Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAG-01 + mitomycin C
- Development stage
- Unknown
- Lead developer
- Ractigen Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravesical
01
Overview
RAG-01 + mitomycin C is an investigational combination therapy being evaluated for the treatment of non-muscle-invasive bladder cancer (NMIBC). RAG-01 is a first-in-class small activating RNA (saRNA) designed to target and upregulate the expression of the p21 (CDKN1A) tumor suppressor gene via RNA activation (RNAa). It is delivered locally via intravesical instillation using Ractigen's proprietary lipid-conjugated oligonucleotide (LiCO™) delivery system. Mitomycin C is a well-established chemotherapeutic agent that acts as a DNA alkylating and cross-linking agent. The combination is designed to leverage the antiproliferative and tumor-suppressive effects of p21 upregulation alongside the cytotoxic DNA-damaging effects of mitomycin C to improve outcomes in patients with intermediate- or high-risk NMIBC.
- Other names
- RAG-01 + MMCRAG-01 and mitomycin CRAG01 and mitomycin CRAG 01 and mitomycin CRAG-01 in combination with mitomycin CRAG01 in combination with mitomycin CRAG 01 in combination with mitomycin C
02
Targets
CDKN1A (Cyclin-dependent kinase inhibitor 1A)DNA
Beyond the preview
Go deeper on RAG-01 + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAG-01 + mitomycin C.